Eli Lilly and Co

LLY is exhibiting a sequence of lower highs and lower lows under declining EMAs, reinforcing a bearish medium-term bias. Short-term trend remains down, with price rejecting rallies into the 9- and 20-day EMA zone despite extreme oversold readings. Execution is advised now on any bounce into the broken EMA region near the mid-$1,100s, with key invalidation being sustained acceptance above the 20-day EMA.

• ↑Q2 revenue $22.97B up 47.7% YoY, driven by Mounjaro and Zepbound
• ↑GLP-1 drugs make up ~65% of sales; Mounjaro surged 91% to $9.9B
• ↓Stretched valuation with low earnings yield and weak book-to-price metrics